文献速递妇科

ATR与PARP抑制剂联合治疗铂耐药复发性卵巢癌的2期研究

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-10-05

CAPRI研究探讨了ceralasertib联合olaparib在铂耐药复发性高级别浆液性卵巢癌中的疗效与安全性。14例可评估毒性患者中,3级不良事件包括恶心(14.3%)等,未观察到客观缓解,但BRCA1突变患者中位无进展生存期达8.2个月,提示该联合方案耐受性良好且可能在BRCA1相关疾病中具有活性信号。

要点

  • ceralasertib联合olaparib方案耐受性良好,主要不良事件为1/2级。
  • 未观察到客观缓解,最佳疗效为疾病稳定(9例)。
  • BRCA1突变患者中位PFS为8.2个月,提示潜在活性信号。

核心结论

  • olaparib联合ceralasertib耐受性良好,未出现客观缓解,但在BRCA1相关疾病中观察到活性信号。
  • 建议在基因组筛选人群中探索替代给药策略。

研究设计与样本

  • CAPRI(NCT03462342)是一项研究者发起的2期研究,采用Simon两阶段设计。
  • 纳入铂耐药复发性高级别浆液性卵巢癌患者,接受ceralasertib 160 mg口服每日一次(第1-7天)联合olaparib 300 mg口服每日两次(第1-28天),28天为一周期。
  • 主要终点为毒性和客观缓解率(RECIST),次要终点为无进展生存期。
  • 14例PARPi初治患者可评估毒性,12例可评估疗效。

主要发现

  • 3例患者携带BRCA1突变(1例胚系,2例体系)。
  • 可能与治疗相关的不良事件主要为1/2级;3级毒性包括恶心(14.3%)、乏力(7.1%)、厌食(7.1%)和贫血(7.1%)。
  • 无客观缓解;最佳疗效为疾病稳定9例,疾病进展3例。
  • 5例患者疾病负荷减少≥20%至<30%,其中3例携带BRCA1突变。
  • 11例可评估患者中3例(27%;2例BRCA1突变)CA-125下降>50%,包括2例CA-125正常化。

关键数值与推荐

  • 主要终点客观缓解率(RECIST)的无效假设为≤5%,若12例患者中≥1例缓解则拒绝无效假设。
  • 3级毒性发生率:恶心14.3%,乏力7.1%,厌食7.1%,贫血7.1%。
  • 总体中位PFS 4.2个月(90% CI: 3.5-8.2),BRCA1突变患者中位PFS 8.2个月(3.6个月-未确定)。

临床怎么用

  • 该联合方案在铂耐药复发性高级别浆液性卵巢癌中耐受性良好,但未显示客观缓解。
  • BRCA1突变患者可能从该联合治疗中获益,需进一步在基因组筛选人群中验证。
  • 临床应用中需关注3级毒性如恶心、乏力、厌食和贫血。

局限性

  • 样本量小(14例可评估毒性,12例可评估疗效)。
  • 未报告盲法或随机化信息。
  • 缺乏对照组,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Platinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited treatment options. Preclinical data suggest that poly(ADP-ribose) polymerase inhibitors (PARPi) and ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) are synergistic. CAPRI (NCT03462342) is an investigator-initiated study of olaparib plus ceralasertib in recurrent HGSOC. Herein, we present results from the platinum-resistant cohort. METHODS: A Simon 2-stage design was utilized. Platinum-resistant HGSOC patients received ceralasertib 160 mg orally daily, days 1-7 and olaparib 300 mg orally twice daily, days 1-28 of a 28-day cycle until toxicity or progression. Primary endpoints were toxicity and efficacy including objective response rate (ORR) by RECIST. Secondary endpoint was progression-free survival (PFS). The null hypothesis (≤5% ORR) would be rejected if there were ≥ 1 responses in 12 patients. RESULTS: Fourteen PARPi-naïve patients were evaluable for toxicity; 12 were evaluable for response. Three had BRCA1 mutations (1 germline, 2 somatic). Adverse events possibly related to treatment were primarily grade (G) 1/2. G3 toxicities included nausea (14.3%), fatigue (7.1%), anorexia (7.1%), and anemia (7.1%). No objective responses occurred. Best response was stable disease in 9 patients and progressive disease in three. Five patients had a ≥ 20% to <30% reduction in disease burden, including 3 with BRCA1 mutations. Three of 11 patients (27%; 2 with BRCA1 mutations) evaluable by Gynecologic Cancer Intergroup criteria had >50% CA-125 decline, including 2 with CA-125 normalization. Median PFS was 4.2 months overall (90% CI:3.5-8.2) and 8.2 months (3.6 months-not determined) for patients with BRCA1 mutations. CONCLUSIONS: Olaparib plus ceralasertib is well-tolerated. No objective responses occurred, though a signal of activity was seen particularly in disease associated with BRCA1. Further evaluation of this combination should include alternate dosing strategies in genomically-selected populations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Shah PD, Wethington SL, Pagan C, et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021. PMID: 34620496. doi:10.1016/j.ygyno.2021.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。